What's Really Happening

Digital health funding had a rough stretch after the pandemic boom fizzled out around 2022 and 2023. That correction is over now. Digital health startups raised about $4 billion in venture capital during the first quarter of 2026, roughly $1 billion more than the same quarter the year before, and the strongest first quarter since the pandemic-era peak. By the middle of the year, digital health companies had raised $7.4 billion in the first half of 2026, up about $1 billion compared to the same period the year prior.

That sounds like a straightforward recovery story. It isn't, really. Dig into where that money actually went and a very different picture shows up.

A handful of companies are eating most of the pie

In the first quarter alone, nearly 60% of all capital deployed came from just 12 large deals. Zoom out to the full first half of the year and the pattern holds: mega deals of $100 million or more absorbed 45% of all deployed capital in H1 2026, concentrating nearly half the market's total funding into just 8% of finalized transactions.

Rock Health, the research group that tracks this space closely, has a blunt name for it: a "haves and have-nots" trend, where some startups quickly attract large rounds while others struggle to raise investment at all. If you're a smaller startup building something genuinely useful but not flashy, that's a hard environment to raise in right now.

AI is doing most of the heavy lifting, for better or worse

You can't talk about digital health funding in 2026 without talking about AI. Companies touting AI offerings made up 54% of total digital health funding last year, up sharply from 37% the year before that. Investors have gotten so used to AI being baked into everything that it's becoming genuinely hard to say which rounds even count as "AI deals" anymore, since AI has become a core focus for nearly every startup pitch.

In practice, this means the label "AI-powered" is doing a lot of marketing work. Some of it is deserved. A meaningful share of this year's biggest rounds went to companies doing real clinical work, not just chatbots with a health skin slapped on. Deals that cleared $100 million this year included companies like Aidoc, working on AI-assisted diagnostic imaging, and OpenEvidence, alongside consumer-health names like Angle Health and Garner Health.

In clinical practice, this distinction matters more than headlines suggest. A well-funded AI diagnostics tool that's been through proper validation is a genuinely different thing from a wellness app riding the same buzzword to a bigger valuation. Patients rarely get to see which is which before they're using the product.

Where the money is actually going

Not every category is getting equal love from investors. Mental health held its position as the top-funded clinical area for the seventh year running, with weight management and obesity care close behind, scaling fast around GLP-1 drugs and the broader consumer peptide market.

There's also a quieter shift happening in how care gets delivered. Capital is moving away from loosely governed, direct-to-consumer chat tools and toward more secure provider marketplaces and multi-specialty clinical platforms, as the industry leans harder into clinical oversight and safeguards. That's a good sign, honestly. It suggests investors are starting to price in the risk of unsupervised AI health advice, rather than just chasing engagement numbers.

On the exit side, the picture is mixed. The market is still waiting on a proper public offering to reopen, with wearable maker Oura reportedly filing at an $11 billion valuation and Whoop closing a $575 million round, but most of the current exit activity is coming from corporate acquisitions and private equity buyouts rather than IPOs. H1 2026 alone saw 115 corporate acquisitions of digital health companies, the busiest stretch for consolidation since late 2021.

What this actually means if you use digital health tools

Funding concentration isn't just a Wall Street story. It shapes which apps survive, which get quietly shut down, and which digital tools your doctor eventually recommends.

A startup that can't raise its next round doesn't usually collapse overnight. It cuts staff, slows updates, or gets bought and folded into something bigger. If you rely on a health app for medication reminders, symptom tracking, or booking appointments, it's worth checking occasionally whether the company behind it is still actively maintained.

This is also why platforms built around connecting patients to real, verified professionals tend to hold up better through funding cycles than single-feature apps chasing the next valuation bump. Whether you're looking for a general physician, searching for a cardiologist, or trying to find a diagnostic centre near you, the underlying service matters more than whichever startup wave built the interface. Booking through verified doctor listings or checking hospital details directly reduces your dependence on any single app's survival.

Telehealth and home-care models, in particular, are proving durable regardless of funding swings, since home visit doctor services and nurse-at-home care solve a real logistical problem rather than chasing a trend. The same goes for practical needs like medicine delivery, pharmacy access, and emergency services — these aren't glamorous funding categories, but they're the ones patients actually depend on daily.

A word on AI diagnostics specifically

Given how much funding is flowing into AI-branded diagnostic startups, it's worth being a little skeptical as a patient. Ask whether an AI tool used in your care has been clinically validated, and by whom. A pediatrician, gynecologist, dermatologist, or endocrinologist using AI-assisted tools should be able to explain, in plain terms, what the software actually does and where a human still makes the final call. If they can't, that's worth noting.

The same goes for surgical and procedural specialties. If you're consulting a surgeon, orthopedist, or gastroenterologist about AI-assisted procedures, ask the same basic questions you'd ask about any new medical technology: how long has it been used, what's the evidence, and what happens if it's wrong.